Continuous Glucose Monitoring Systems Market

Market Overview:

The global continuous glucose monitoring systems market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 5.7% during 2023-2028.

Continuous glucose monitoring systems (CGMS) are technologically advanced devices that automatically track blood glucose levels. They consist of a transmitter-integrated sensor that functions through a transcutaneous or subcutaneous route to continuously measure the glucose concentration in interstitial fluid. The transmitter then sends the information to a wireless monitor that can be clipped to clothes. Continuous glucose monitoring systems assist in providing a complete profile of diabetes, alerting highs and lows of blood sugar levels, detecting patterns, and increasing patient insights regarding physical activity, medication choices, food portions and stress. As compared to conventional glucose monitoring devices, CGMS are prick-free as they can be placed over the skin, thus aiding in providing real-time information in a quick and painless fashion.

Continuous Glucose Monitoring Systems Market Trends:

The rising geriatric population across the globe that are more susceptible to developing diabetes is creating a positive outlook for the market. CGMS is commonly used for measuring glucose and insulin level in the body, which further sounds an alarm if it drops or rises to a dangerous level. In line with this, the widespread product utilization to identify hypoglycemia and hyperglycemic situations in real-time is favoring the market growth. Moreover, significant improvements and new technological advancements in CGMS that aid in detecting glycated hemoglobin (Hb1ac) in patients with diabetes are providing a considerable boost to the market growth. Additionally, the integration of artificial pancreas device systems with CGMS technology to pump insulin and administer optimum dosage to manage the blood sugar levels of patients is positively impacting the market growth. Apart from this, the introduction of non-invasive CGMS devices as a convenient alternative, extensive research and development (R&D) activities and the increasing demand for less or minimally invasive diagnostic tools are anticipated to drive the market further toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global continuous glucose monitoring systems market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, demographics and end user.

Breakup by Component:

• Sensors
• Transmitters and Receivers 
• Integrated Insulin Pumps
   

Breakup by Demographics:

• Child Population (≤14 years)
• Adult Population (>14 years)
   

Breakup by End User:

• Clinics and Diagnostics Centers
• ICUs
• Home Healthcare
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc.

Report Coverage: